The relationship between weight status and metabolic syndrome in patients with rheumatoid arthritis and spondyloarthritis - 11/02/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Metabolic health is not uniform among RA and SpA patients with similar BMI. |
• | In RA, metabolic syndrome did not increase with bodyweight and was not associated with fat. |
• | Conversely, in SpA metabolic syndrome was associated with body fat and cardiovascular risk. |
Abstract |
Objectives |
To compare the prevalence and correlates of metabolic syndrome (MetS) stratified by body mass index (BMI) categories in rheumatoid arthritis (RA) and spondyloarthritis (SpA).
Methods |
The age- and sex-standardized prevalence of MetS was calculated by BMI categories and compared between RA and SpA patients before starting first biologic, and controls. The determinants of metabolic syndrome in patients without obesity were investigated.
Results |
MetS was observed in 28% of RA (21/75), 22.5% of SpA (18/80), 19% of controls (187/998). The age- and sex-standardized prevalence of MetS was not significantly different between RA 19% (95% CI: 11–27%), SpA 26% (95% CI: 16–36%) and controls 16% (95% CI: 14–18%). When stratified by BMI, the standardized prevalence of MetS was less frequent in obese RA patients (15%, 95% CI: 4–27%) compared to obese controls (48%, 95% CI: 40–55%) or to obese SpA (36%, 95% CI: 26–45%). In normal-weight RA patients, MetS standardized prevalence was 16% (95% CI: 7–25%) compared to 5% (95% CI: 0–11%) in SpA, and 6% (95% CI: 4–8%) in controls. In non-obese SpA, MetS was associated with abdominal obesity, visceral fat mass and cardiovascular risk. In non-obese RA patients with metabolic syndrome, body composition did not differ from metabolically healthy RA patients.
Conclusions |
MetS is not uniform among patients with similar BMI. In RA, MetS was less frequent in obese patients, and unlike SpA, was not associated with body fat composition in non-obese patients. Differences between RA and SpA for metabolic health suggest various pathophysiological mechanisms.
Le texte complet de cet article est disponible en PDF.Keywords : Metabolic syndrome, Obesity, Rheumatoid arthritis, Spondyloarthritis
Plan
Vol 88 - N° 1
Article 105059- janvier 2021 Retour au numéro
Article précédent
- Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients
- Eun Hye Park, Anna Shin, You-Jung Ha, Yun Jong Lee, Eun Bong Lee, Yeong Wook Song, Eun Ha Kang
- Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis
- Jasvinder A. Singh, Haley Tornberg, Susan M. Goodman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?